Articles tagged with: MLN9708
A new year is upon us. I hope it has started well for everybody, and that all had a great holiday season!
The last few weeks of 2014 were a happening time for the multiple myeloma community. The short span of time witnessed the publication of updated criteria for the diagnosis of multiple myeloma from the International Myeloma Working Group (IMWG), as well as the 56th annual meeting of the American Society of Hematology (ASH) in San Francisco.
Therefore, it is again time to take a little quiz to test …
The 2014 annual meeting of the American Society of Hematology (ASH) starts tomorrow, December 5, in San Francisco, and will continue until next Tuesday.
The ASH annual meeting is one of several large medical conferences where myeloma-related research findings are presented each year. However, from a multiple myeloma perspective, the ASH meeting is generally the most important of the meetings.
At this year’s meeting, for example, some 500 myeloma-presentations are scheduled to take place. The presentations will summarize current research on a wide range of topics, including the biology of …
Monday was the third day of this year’s meeting of the American Society of Hematology (ASH). The day was filled with oral presentation sessions from early in the morning until into the evening.
In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon. The topics of these presentations ranged from the biology of myeloma to treatment options for newly diagnosed, relapsed and refractory, and older patients.
This ASH update highlights most of …
This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in New Orleans.
Myeloma-related presentations were made during several sessions yesterday.
Two sessions were designed to better educate physicians about multiple myeloma and how to treat the disease.
The key myeloma-related research presented yesterday was made public during a poster session in the evening about the biology of myeloma as well as preclinical and clinical studies testing new and existing treatments for myeloma.
During the session, research results were made available for review by meeting attendees in …
The Beacon continues today with its ‘ASH preview’ series about myeloma research that will be presented at the American Society of Hematology (ASH) meeting in early December.
Abstracts for the ASH presentations are now available, although many contain preliminary information that will be updated at the meeting.
The Beacon’s ASH preview articles are intended to highlight the meeting's most interesting myeloma-related studies.
The first and second previews, published earlier this week and last week, provide an overview of ASH abstracts about the newest potential myeloma therapies just starting out in clinical trials. Further …